Skin Tau Quantification as a Novel Biomarker in Huntington’s Disease
Objective: To explore skin tau quantification as a potential biomarker for disease severity, motor and cognitive function in Huntington's disease Background: Beyond the aggregation of…7year followup of Asia’s first case of sporadic ATP6AP2 Mutation: α-synucleinopathy or tauopathy?
Objective: ATP6AP2 mutation, previously described in literature to cause early onset Parkinson’s disease (PD) with atypical signs, evolved into frontotemporal lobar degeneration in a 7year…Lingual-Masticatory Myorhythmia and Palatal Tremor as a Presentation of Anti-IgLON5 Disease
Objective: Anti-immunoglobulin-like cell adhesion molecule-5 (anti-IgLON5) disease may manifest with spectrum of various neurological presentations and movement disorders, including prominent sleep movement disorders, bulbar symptoms,…Dermal 4R-Tau seeding as a novel biomarker for Progressive Supranuclear Palsy
Objective: To ascertain the presence of misfolded tau species in the skin of Progressive Supranuclear Palsy (PSP) patients and evaluate its utility as a potential…Is cathepsin D a good target for therapy in Tau-related conditions?
Objective: To study the involvement of cathepsin D in the pathogenesis of Tau-related conditions. Background: The endo-lysosomal system (ELS) is central in processing of neurodegenerative…Tau Deposition in Locus Coeruleus is Associated with Rapid Eye Movement Sleep Behavior Disorder in Progressive Supranuclear Palsy.
Objective: In this study, we aimed to investigate the frequency of Rapid eye movement sleep behavior disorder (RBD) occurring in a large cohort of PSP,…Longitudinal progress and clinical relevance of 18F-Florzolutau PET in patients with PSP: a one-year follow-up study
Objective: Here we aimed to explore the progress of 18F-Florzolotau PET and its clinical relevance in patients with PSP during one-year follow-up. Background: The 18F-Florzolotau…Clinical and neuroimaging factors associated with survival in Progressive Supranuclear Palsy
Objective: To assess clinical and neuroimaging factors associated with survival in a cohort of patients with a final clinical diagnosis of Progressive Supranuclear Palsy (PSP)…Development and Validation of a Clinical Scale for Distinguishing Multiple System Atrophy from 4-Repeat Tauopathies
Objective: We aimed to develop a clinical scale that distinguishes between Multiple System Atrophy (MSA) and 4-repeat tauopathies (4RT: CBD, PSP) using a standardized neurological…Environmental risk factors and demographic of patients with Progressive Supranuclear Palsy from Argentina
Objective: To describe the environmental risk factors and family history in Argentinian patients with diagnosis of progressive supranuclear palsy (PSP). Background: Background: The current epidemiology…
- 1
- 2
- 3
- …
- 13
- Next Page »